Accelerated streptokinase in ST-elevation myocardial infarction--a Romanian (ASK-ROMANIA) multicenter registry.

Background: The classical streptokinase regimen (1.5 M.U.

Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).

Unlabelled: The Streptokinase (SK) regimen (1.5 MU/60 minutes) has remained unchanged for the past 20 years in patients with ST-segment elevation acute myocardial infarction (STEMI) due to fear of hypotension (a specific effect of this thrombolytic agent) and of hemorrhagic complications.

Objective: To evaluate the influence of the Streptokinase-induced hypotension (SK-hTA) on the rate of coronary reperfusion (CR), incidence of cardiogenic shock (CS), 30-day mortality and incidence of stroke in patients (pts.

Double bolus of 0.75 MU streptokinase plus enoxaparin versus front-loaded alteplase plus unfractionated heparin in ST-segment elevation myocardial infarction.

Objective: To compare the efficacy and safety of an accelerated streptokinase regimen (double bolus of 0.75 MU in 10 min) in combination with enoxaparin (SK0.75Enox regimen) with the one of the front loaded alteplase (t-PA 100 mg/90 min) plus heparin (the t-PAHep regimen) in patients (pts.

Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study).

Background: The streptokinase (SK) regimen (1.5 MU/60 min) has remained unchanged in the ST-segment elevation acute myocardial infarction (STEMI) for the last 20 years.

Aim: To compare the efficacy of an accelerated SK (ASK) regimen combined with enoxaparin (Enox) or heparin (UFH) with the standard SK and UFH combination in STEMI.

Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarction.

Objective: To compare a new streptokinase regimen combined with either enoxaparin or unfractionated heparin (UFH) and the traditional streptokinase regimen combined with UFH in patients with acute myocardial infarction (AMI).

Methods: 412 patients (<75 years), hospitalized within 6 hours of the onset of chest pain, were allocated thrombolytic therapy by the treating physician: streptokinase 0.75 MU/10 minutes, repeated if no coronary reperfusion after one dose, plus enoxaparin 40 mg intravenously followed by 1 mg/kg bodyweight subcutaneously at 12-hour intervals for 5-7 days (n = 102); the same streptokinase regimen plus UFH 1000 IU/60 minutes intravenously for 48-72 hours ( n = 106); or streptokinase 1.

QT & RR variability spots the earliest autonomic deregulation in diabetes. Fading of vagal sino-atrial drive but not of sympathetic ventricular responsiveness to life challenges.

27 consecutive insulin-dependent diabetic patients (pts), under 50 years, with blood glucose controlled within normal limits and no significant or multiple cardiovascular/neurological complications in the lights of clinical tests, went through a protocol as follows: laiddown at relaxed rest for 10 min, then stood-up quietly for 7 min, and finally experienced a stress-interview for 10 min while supine. A thoracic ECG lead was digitized at I ms (Codas, Dataq Instr.), RR and QT intervals were software-detected, resampled at 500 ms, and Fourier-transformed over 3 min epochs to get auto-or cross-spectra.